Brought to you by 
Amicus buys Celenex for up to $452mm, acquiring ten rare disease pipeline programs
24 Sep 2020
Executive Summary
Supporting its business strategy to move into the gene therapy arena, Amicus Therapeutics Inc. agreed to acquire privately held Celenex (gene therapies for neurological lysosomal storage disorders (LSDs)), gaining ten rare disease pipeline projects.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amicus buys Celenex for up to $452mm, acquiring ten rare disease pipeline programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice